Table 5 Candidiasis treatment with potential liposomal vaccines
From: Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines
Lipid(s) and sterol used | Fungi or disease | Cell line/animal model used | Administration route | Promising liposome formulation | References |
|---|---|---|---|---|---|
PC/Chol | C. albicans and C. tropicalis | BALB/cByJ mice | Intravenous | PC/Chol | [106] |
PC/Chol | BALB/c mice | Intravenous | PC/Chol | [107] | |
DMPC/DMPG | C. albicans | ICR mice | Subcutaneous | DMPC/DMPG | [108] |
EPD/DOGS-NTA-Ni | BALB/c mice | Intradermal | EPD/DOGS-NTA-Ni | [109] | |
ICR mice | Intradermal | [110] | |||
DDA:MO | Macrophages and BALB/c mice | Subcutaneous | DDA:MO | [111] | |
BALB/c mice | Subcutaneous | [112] |